Mackenzie Financial Corp Has $11.44 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Mackenzie Financial Corp grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 69.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 115,007 shares of the company’s stock after buying an additional 46,964 shares during the quarter. Mackenzie Financial Corp’s holdings in Moderna were worth $11,437,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors increased its holdings in shares of Moderna by 6.5% during the fourth quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 2,459 shares of the company’s stock valued at $245,000 after acquiring an additional 151 shares in the last quarter. Conning Inc. acquired a new stake in Moderna in the 4th quarter valued at $207,000. Vontobel Holding Ltd. increased its stake in Moderna by 6.8% during the 4th quarter. Vontobel Holding Ltd. now owns 55,799 shares of the company’s stock valued at $5,549,000 after purchasing an additional 3,576 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Moderna by 16.6% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,081,869 shares of the company’s stock worth $107,592,000 after buying an additional 154,112 shares during the last quarter. Finally, Louisiana State Employees Retirement System bought a new position in shares of Moderna in the fourth quarter valued at $5,012,000. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 544 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the sale, the insider now directly owns 9,267 shares of the company’s stock, valued at $917,896.35. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CFO James M. Mock sold 647 shares of Moderna stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the transaction, the chief financial officer now directly owns 4,300 shares in the company, valued at $406,651. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Shannon Thyme Klinger sold 544 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $99.05, for a total value of $53,883.20. Following the sale, the insider now owns 9,267 shares in the company, valued at $917,896.35. The disclosure for this sale can be found here. In the last 90 days, insiders sold 109,954 shares of company stock valued at $11,533,976. 15.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on MRNA shares. William Blair reissued a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target for the company in a research note on Tuesday, January 2nd. Jefferies Financial Group reissued a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Thursday, April 11th. Finally, Canaccord Genuity Group upped their price target on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a report on Friday, February 23rd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $126.49.

Moderna Trading Down 0.6 %

Shares of MRNA stock opened at $101.41 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The company has a 50 day moving average of $100.63 and a 200-day moving average of $93.64. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $144.43.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. During the same period last year, the business posted $3.61 earnings per share. The business’s revenue for the quarter was down 44.9% on a year-over-year basis. As a group, analysts predict that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.